Sixth Street Renews $70-a-Share Bid for Brighthouse Financial as Aquarian Deal Stalls, September 2026: What Finance Teams Must Watch

This is a factual summary based on public reporting and regulatory filings as of September 26, 2026, and is not investment, legal or actuarial advice. Companies with exposure to Brighthouse products or securities should consult their own advisors.

What is actually happening with the Brighthouse deal?

Brighthouse Financial — the life insurance and annuity company spun off from MetLife in 2017 — agreed last year to be acquired by Aquarian Holdings in an all-cash deal valuing the company at $70.00 per share, or roughly $4.1 billion. Brighthouse stockholders approved the merger at a special meeting, which is normally the last major hurdle before a deal like this closes. It was not. Insurance holding-company acquisitions of this size also require state insurance regulators to approve a “Form A” change-of-control filing, and Delaware — Brighthouse’s domiciliary state for its principal insurance subsidiaries — is where that review sits.

According to Bloomberg’s September 22 report, Delaware’s insurance regulator is now scrutinizing the funding sources behind Aquarian’s bid, and that review has been pushed out to December 6, 2026. That is a meaningful delay for a deal that was supposed to be moving toward close. In the gap it has opened, Talcott Financial Group — the life and annuity insurer backed by investment firm Sixth Street — sent Brighthouse’s board a private letter last month reaffirming its desire to acquire Brighthouse if the Aquarian transaction falls apart. Talcott had previously been reported to have floated a $55-a-share offer earlier in the process, before Aquarian’s higher bid won out.

The market’s read is visible in the stock price: Brighthouse shares have been trading near $51.90, a substantial discount to the $70.00 deal price. A wide spread between a target’s share price and its announced deal price is one of the clearest signals professional investors use to price in deal risk — here, the risk that the Aquarian transaction is delayed, renegotiated at a lower price, or does not close at all.

Why is a state insurance regulator holding this up?

Change-of-control reviews for insurers are not rubber stamps. State insurance departments are required to evaluate whether an acquirer has the financial strength, and legitimate, sufficiently liquid funding, to support the insurer’s long-term obligations to policyholders — obligations that, for an annuity and life insurer like Brighthouse, can run for decades. Regulators have become noticeably more careful in recent years about acquisitions of life insurers by private-capital-backed buyers, because these buyers frequently fund deals with a mix of equity, third-party debt, and sometimes affiliated financing structures that can be harder to evaluate than a strategic acquirer’s balance sheet.

That scrutiny sits inside a broader, well-documented trend: private equity and alternative-asset-manager ownership of life and annuity insurers has grown steadily over the past decade, driven by the insurers’ large, long-duration investment portfolios, which sponsors can redeploy into higher-yielding private credit and other alternative assets. Regulators, rating agencies and policyholder advocates have all flagged the same set of questions about this ownership model: is the acquirer’s funding durable, does the post-deal investment strategy introduce new asset-liability mismatch or liquidity risk, and are affiliated transactions (such as related-party reinsurance) priced and structured on terms that protect policyholders. A Delaware review that specifically targets “funding sources” fits squarely inside that pattern, even though the regulator has not publicly detailed its exact concerns.

What are the possible outcomes?

Broadly, four paths are on the table. First, Aquarian could satisfy Delaware’s questions about its funding sources before December 6 and proceed to close on the original $70.00-a-share terms — the outcome Aquarian and Brighthouse’s board publicly remain committed to. Second, the parties could renegotiate price or deal structure to address regulatory or financing concerns, which would likely disappoint shareholders who already voted to approve the higher price. Third, the Aquarian deal could be terminated — whether by regulatory rejection, financing failure, or a decision by either party to walk away — which would trigger termination-fee provisions in the merger agreement and reopen the field. Fourth, and this is the scenario Talcott’s letter is positioning for, Sixth Street’s insurance platform could return with a competing offer if the Aquarian deal fails, though its most recently reported bid level ($55 a share) sits well below Aquarian’s $70.00 headline price.

None of this means Brighthouse is in financial distress. The company continues to operate, write and administer policies, and meet its regulatory capital requirements as an ongoing insurer regardless of who eventually owns its parent holding company. What is unresolved is purely the ownership transaction and the price at which it happens.

Why this matters beyond one insurance deal

For finance and corporate-development teams, the Brighthouse situation is a live case study in a pattern that keeps recurring across the insurance sector in 2026: regulators are willing to slow down, and in some cases reshape, private-capital acquisitions of life and annuity insurers, even after shareholders have already voted yes. Any company that is (a) evaluating a life insurer or annuity provider as an acquisition target or strategic partner, (b) relying on annuity products from a company currently subject to a pending change of control, or (c) structuring its own financing for an insurance-adjacent acquisition should treat “funding-source transparency” as a first-order diligence item, not an afterthought late in the process.

There is also a market-signal lesson here for corporate treasury and investor-relations teams that track M&A arbitrage spreads as a proxy for macro risk appetite: a nearly 26% gap between Brighthouse’s trading price and its deal price, five months before the merger agreement’s original expected close window, is an unusually wide spread for a definitively signed, shareholder-approved transaction. It reflects real uncertainty priced in by risk-arbitrage desks, not just noise.

Concrete steps for this week

If your organization has any exposure to Brighthouse — as a counterparty, a reinsurer, a distributor of its annuity products, an institutional shareholder, or a company benchmarking your own insurance M&A strategy — take these steps now. Pull the most recent 8-K or equivalent disclosures from Brighthouse and Aquarian for any updated language on the Delaware review timeline. Check your own contracts with Brighthouse for change-of-control notice or consent provisions and confirm who owns tracking that obligation internally. If you are a shareholder or hold related derivatives, brief your risk committee on the current arbitrage spread and the December 6 decision date so it is not a surprise event. If you sit on a corporate development team evaluating your own insurance-sector acquisition, add a specific “financing-source transparency” diligence question to your regulatory-approval risk assessment, informed directly by what Delaware is asking of Aquarian.

What to watch next

The near-term calendar item is December 6, 2026, when Delaware’s insurance regulator is expected to conclude its review of Aquarian’s funding sources. Watch for any interim disclosure from Aquarian, Brighthouse or the Delaware Department of Insurance narrowing or clarifying the specific funding concerns. Watch Brighthouse’s share price relative to $70.00 as a running indicator of market-implied deal-completion odds. And watch whether Brighthouse’s board issues any statement responding to, or distancing itself from, Talcott’s approach — silence from the board so far is consistent with a company that remains contractually committed to the Aquarian deal and is not yet free to negotiate with a third party.

Sources: Bloomberg, “Sixth Street Renews Brighthouse Bid as Aquarian Deal Faces Regulatory Review,” September 22, 2026; Brighthouse Financial stockholder merger-approval disclosure; Aquarian Holdings/Brighthouse Financial merger agreement filings; InvestmentNews coverage of the original Aquarian-Brighthouse transaction.